
==== Front
BMJ Open Ophthalmol
BMJ Open Ophthalmol
bmjophth
bmjophth
BMJ Open Ophthalmology
2397-3269
BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR

39209740
10.1136/bmjophth-2024-001764
bmjophth-2024-001764
Original Research
1506
Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database
http://orcid.org/0000-0001-9918-2024
Contreras-Salinas Homero 1homero.contreras@sophia.com.mx

Romero-López María Soledad 1soledad.romero@sophia.com.mx

Olvera-Montaño Oscar 2oscar.olvera@sophia.com.mx

Rodríguez-Herrera Lourdes Yolotzin 1lourdes.rodriguez@sophia.com.mx

1 Pharmacovigilance Department, Laboratorios Sophia SA de CV, Zapopan, Jalisco, Mexico
2 Clinical Research, Laboratorios Sophia SA de CV, Zapopan, Jalisco, Mexico
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Supplement: Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/bmjophth-2024-001764).

Laboratorios Sophia provided support in the form of salaries for authors (HC-S, MSR-L, OOM, LYR-H), but did not have any additional role.

DrHomeroContreras-Salinas; homero.contreras@sophia.com.mx
2024
29 8 2024
9 1 e00176410 5 2024
15 8 2024
Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Abstract

Objective

This study aims to identify safety signals of ophthalmic prostaglandin analogues through data mining the Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods

A data mining search by proportional reporting ratio, reporting OR, Bayesian confidence propagation neural network, information component 0.25 and χ2 for safety signals detection was conducted to the FAERS database for the following ophthalmic medications: latanoprost, travoprost, tafluprost and bimatoprost.

Results

12 preferred terms were statistically associated: diabetes mellitus, n=2; hypoacusis, n=2; malignant mediastinal neoplasm, n=1; blood immunoglobulin E increased, n=1; cataract, n=1; blepharospasm, n=1; full blood count abnormal, n=1; skin exfoliation, n=1; chest discomfort, n=1; and dry mouth, n=1.

Limitation of the study

The FAERS database’s limitations, such as the undetermined causality of cases, under-reporting and the lack of restriction to only health professionals reporting this type of event, could modify the statistical outcomes. These limitations are particularly relevant in the context of ophthalmic drug analysis, as they can affect the accuracy and reliability of the data, potentially leading to biased or incomplete results.

Conclusions

Our findings have revealed a potential relationship due to the biological plausibility among malignant mediastinal neoplasm, full blood count abnormal, blood immunoglobulin E increased, diabetes mellitus, blepharospasm, cataracts, chest discomfort and dry mouth; therefore, it is relevant to continue investigating the possible drug-event association, whether to refute the safety signal or identify a new risk.

Drugs
Epidemiology
Glaucoma
Medical Education
Pharmacology
==== Body
pmcWHAT IS ALREADY KNOWN ON THIS TOPIC

Prostaglandin analogues can mimic the effects caused by endogenous prostaglandins, which modify multiple organs and tissues in the body and, therefore, could trigger unexpected side effects.

WHAT THIS STUDY ADDS

Data mining is a tool that allows the adequate analysis of prostaglandin analogues’ drug side effects in a database to identify statistical associations that lead to the identification of new risks.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

The identification of new risks could impact in the benefit–risk balance of these drugs and trigger activities focused on minimising them.

Introduction

The currently available pharmacological treatments for glaucoma include: alpha-adrenergic agonists, beta-adrenergic antagonists, prostaglandin analogues (PGAs), cholinergic and carbonic anhydrase inhibitors, with PGAs being the drug of choice due to their safety profile.1

Prostaglandins (PGs) are molecules derived from arachidonic acid, metabolised by cyclooxygenases; these include the following five types: prostaglandin E (PGE), prostaglandin F (PGF), prostaglandin I, prostaglandin D and thromboxane A.2 Additionally, PGs induce the activation of broad different cell types, triggering diverse actions, that is, inflammation, modifications in the sleep cycle, membrane transport, synaptic modulation of the nervous system, cell cycle and blood flow regulation, among others.3

At present, all commercially available PGAs are prostaglandin F2α (PGF2α) prodrugs such as: latanoprost, travoprost and tafluprost. Alternately, bimatoprost is a synthetic analogue of an endogenous prostamide, binding to prostaglandin F receptors.1 4 However, due to the relatively non-selective nature of PGF2α, the molecule can activate prostaglandin E receptors (EP), which could be responsible for unexpected adverse events (AEs).4

Commonly expected AEs for PGAs include: conjunctival hyperaemia, conjunctival allergy, blepharitis and corneal epithelial disorders, among others.59 However, unexpected AEs (not mentioned in the safety information label) may occur and should be analysed as a safety signal. Once the drug-event association has been determined, they should be listed as a new risk.10 11 Due to this, the determination of safety signals from unexpected AEs must be analysed to identify new risks that could impact the risk-benefit balance of drugs.1114 Nowadays, there are tools that allow the detection of safety signals, for example, data mining, which pinpoint statistical associations between drugs with unexpected AEs in safety report databases.15 Moreover, due to PGs exerting effects on different cell types around the body that PGs could activate due to their analogy, it is essential to identify the possible association that could cause the use of PGAs in ophthalmologic practice. This study aims to identify safety signals of ophthalmic PGAs by data mining the Food and Drug Administration’s Adverse Event Reporting System (FAERS) database.

Methods

Data standardisation

All the AEs within the FAERS database are grouped in System Organ Classes (SOCs) and Preferred Terms (PTs) levels of the Medical Dictionary for Regulatory Activities, which have five hierarchical levels: Lowest Level Terms, PTs, High Level Terms, High Level Group Terms and SOCs.16

Study design

A meticulous search was conducted in the FAERS database, focusing on the following ophthalmic drugs: latanoprost, travoprost, tafluprost and bimatoprost, with a cut-off date of Q4 2022. The FAERS data were then meticulously processed to eliminate duplicate data submitted by multiple individuals and institutions. This involved a careful selection process: If two or more reported CASEIDs (the number to identify a FAERS case) were the same, the last one FDA_DT (the date the FDA received the case) was selected. If CASEID and FDA_DT were equal, the highest PRIMARYID was selected (a unique number to identify a FAERS report). Finally, the following data were not analysed (selection criteria): less than 10 AEs in the database, AEs derived from quality problems, medication errors, lack of efficacy and expected AEs based on summary of product characteristics (SmPC) of Food and Drug Administration’s New Drug Application (XALATAN latanoprost/ Pfizer Laboratories5; TRAVATAN Z travoprost solution/Novartis Pharmaceuticals7; ZIOPTAN tafluprost solution/Akorn9; LATISSE bimatoprost solution/Allegan)8 (figure 1). Since FAERS is a voluntary reporting system with inconsistencies, only signals in all methods were used, reducing the type I error (decreasing the risk of false positives).

Figure 1 Study design. Adverse Events (AEs). Preferred Terms (PTs).

Methods for data mining

Reporting odds ratio

To calculate the OR for a specific adverse event associated with a particular drug, one must divide the ratio of the probability of these adverse events with the drug of interest by the ratio of the probability of the same adverse event occurring relative to all other adverse events. Formulation: (probability/1−probability).17

Proportional reporting ratio

The proportion of adverse events reported for a specific drug, relative to the proportion of adverse events reported for all other drugs within the database, represents the observed-to-expected ratio for that adverse event. The ratio provides a measure of the frequency of the adverse event associated with the drug in comparison to its expected frequency based on the broader database.17

Bayesian Confidence Propagation Neural Network

The quantitative method employed involves using log-based 2 to calculate the ratio of observed to expected adverse events. This approach incorporates a shrinkage adjustment to reduce the impact of sparse data by constraining the information component (IC) towards a null value of 0, thereby mitigating the risk of false positives.18 19 This method is used at the Uppsala Monitoring Centre for signal detection purposes.20

Chi-square

The test evaluated the association between variables by comparing the observed frequency in each cell to the expected frequency, employing the χ2 test with 1 df.21

In this manuscript, we have used all the aforementioned methods, as each demonstrates improvements in specific analyses. Consequently, it is challenging to designate a single algorithm as the superior approach for all types of associations.17

Disproportionality analysis for data mining

The following methods were performed: proportional reporting ratio (PRR)±CIs (95%), (Equation 1); reporting OR (ROR)±CI (95%), (Equation 2); Bayesian Confidence Propagation Neural Network (BCPNN)+information component 0.25 (IC025) (95%), (Equation 3); and χ2 (statistical significance at a p value≤0.05) (Equation 4).

The criteria used to define a signal of disproportionate reporting were in accordance with ‘Practical Aspects of Signal Detection in Pharmacovigilance’, Council for International Organizations of Medical Sciences, 2010 (PRR and ROR: CI>2; IC025>0; χ2>4).17

Equation 1: proportional reporting ratio

PRR=(AA+B)/(CC+D)

CI(±)=(e(ln⁡(PRR)±1.96)) (ba(a+b))+(dc(c+d))

Equation 2: reporting OR

ROR=ADCB

CI(±)=(e(ln⁡(ROR)±1.96)) 1A+1B+1C+1D

Equation 3: Bayesian Confidence Propagation Neural Network

BCPNN=log2((A)((A+B+C+D)(A+B)(A+C)))

IC025=(e(ln⁡(BCPNN)−1.96)) 1A+1B+1C+1D

Equation 4: χ2 test

X2=∑i=1n((Oi−Ei)2Ei)

Notations for equations:

A=Interaction between reports for PGs and reports for AEs of interest.

B=Interaction between reports for PG and reports for all other AEs.

C=Interaction between reports for all other drugs and reports for AEs of interest.

D=Interaction between reports for all other drugs and reports for all other AEs.

Results

A total of 26 004 135 AEs were displayed in the FAERS database. PGAs AEs were classified in 6361 different PTs, of which only 12 fulfilled the selection criteria (figure 1), (diabetes mellitus, n=2; hypoacusis, n=2; malignant mediastinal neoplasm, n=1; blood immunoglobulin E increased, n=1; cataract, n=1; blepharospasm, n=1; full blood count abnormal, n=1; skin exfoliation, n=1; chest discomfort, n=1; and dry mouth, n=1). These were distributed in 8 SOCs (eye disorders, n=2; ear and labyrinth disorders, n=2; investigations, n=2; metabolism and nutrition disorders, n=2; gastrointestinal disorders, n=1; skin and subcutaneous tissue disorders, n=1; general disorders and administration site conditions, n=1; neoplasms benign, malignant and unspecified, n=1). A total of 10 presented a p value<0.00001 (PRR: 3046.8–2.0, ROR: 3064.4–2.0, IC 10.3–1), one with 0.010844 and another with 0.017948 (online supplemental table 1).

Most subjects were women (ranged from 46% for skin exfoliation up to 100% for full blood count abnormal) between 65 and 85 years of age and the ophthalmic drug travoprost showed the highest incidence of serious AEs (all serious) (online supplemental table 2).

Discussion

Statistical associations in data mining are the initial part of identifying a new risk since information from the literature, preclinical, clinical trials and post-marketing studies is required to issue the closure of safety signals.11 22 Even if such an association is found, it must be determined whether the route and the dose are sufficient to be considered risks for a particular indication.13 However, the first step in safety signal analysis is finding biological plausibility between the drug and the event, to explain potential mechanisms.

Our results show that the PT with the most statistical association of PRR, ROR and IC025 AE is a malignant mediastinal neoplasm belonging to the SOC neoplasms benign, malignant and unspecified (including cysts and polyps), of which various sources identify PGs as part of a significant role in the development of various types of cancer via increased tumour proliferation, survival and metastatic capacity, by PGA2, PGE1, PGE2 and PGF2α receptors.2327

PGE2, the most prevalent PG found in various human malignancies, promotes tumour growth and progression.2830 Its interaction with oncogenic signalling pathways, such as epidermal growth factor and its receptor, phosphoinositide 3-kinase, protein kinase Akt, b-catenin, mitogen-activated protein kinase and adenylyl cyclase activation, is a significant area of study.28 29 These pathways are known to be related to the development and progression of cancer.29 30 Furthermore, the changes in the tumour microenvironment mediated by immune cells responding to PGE2 influence are also crucial in understanding cancer progression.31

Of particular concern is the abnormal or high expression of EP receptors, especially the EP2 receptor.28 29 These receptors, belonging to the G-protein coupled receptor family, have been linked to functions such as carcinogenesis and play a role in aberrant intracellular signal transmission that is commonly linked to tumour growth and metastasis.29

PGE2 plays a significant role in cancer progression by suppressing innate and antigen-specific immunity. It reduces the activities of interleukins such as IL-2, IL-12, and IL-15, thereby suppressing the cytotoxic functions and interferon production of natural killer cells.30 This immune suppression by PGE2 contributes to promoting cancer development and progression.

Contrasting the SOC ‘Investigations’ with literature reports, we have found the effects of PGs on blood cells and the immune system. For example, Carini et al found that PGF2α has a dual effect: it stimulates division in certain cell lines while inhibiting growth in others. that is, an increase in the division of circulating B lymphocytes32 and a decrease in the number of neutrophils,33 also, it has been mentioned the immune-suppressing effect of PGE2 by inhibition of T-cell proliferation and the regulation of dendritic cell maturation34; which could result in a full blood count abnormal. Cianferoni mention that some inflammatory mediators, such as bradykinin or PGs can modulate the activation of mast cells and basophils, causing vasodilation and bronchoconstriction, resulting in anaphylaxis-type reactions.35 Additionally, Gao et al described the increase in IgE release by EP2 receptors, facilitating the activation of IL-4,36 that could trigger a blood immunoglobulin E increased with the use of PGAs.

Several sources describe an association between PGs and fat metabolism, obesity and diabetes.3740 Furthermore, some authors showed the inhibition of glucose-stimulated insulin secretion (GSIS) by PGE2,4043 however, in the research of Carboneau et al, this appears to be receptor-dependent as some PG receptors increase and others decrease ß-cell survival, producing the stimulation or inhibition of insulin secretion depending on the PG receptor activation.39 On the other hand, Lee et al, found that a hyperglycaemia-induced PG production mechanism affects the neuronal activity in the medial part of the hypothalamus, probably by changing the activities in the ion channel, and it seems that PGs regulate GSIS from pancreatic beta cells in a similar way, which can respond to modifications in glucose metabolism.44 This information could explain the increase in the recurrence of diabetes mellitus diagnosis with the use of PGAs in the FAERS database.

The SOC ‘Eye Disorders’ have also been contrasted with scientific literature. First, Matsuo et al the association of Müller’s muscle and blepharospasm due to an increase in the contraction of the orbicularis oculi muscle is reported.45 On the other hand, PGs and their analogues reveal contraction (Ca+2) and relaxation (cAMP) on Müller’s muscle.4648 therefore, blepharospasm could be explained by the stimulation of the PGs receptors located in the Müller’s muscle.

On the other side, Andley et al mentioned in 1994 that the activation of PGE2 could be involved in the posterior subcapsular cataract.49 However, Goto et al showed that even though there is an increase in the synthesis of molecules involved in the formation of cataracts (PGE2, IL-1α and IL-6) with latanoprost, the synthesis of these molecules is considerably higher with benzalkonium chloride,50 which is the most widely used preservative in ophthalmic formulations. This risk is already labelled in the SmPC for travoprost, tafluprost and bimatoprost.79

Concerning SOC ‘Gastrointestinal Disorders’, various investigations mention PGs as molecules involved in decreased salivation related to calcium metabolism and inflammation, causing dry mouth.5153 This had already been published in 1986 by Yu, where rats were administered different prostanoids (PGE1, PGE2 and PGF2α). A decrease in the flow of submandibular saliva mediated by the decrease in the concentration and flow of calcium in nerve-evoked salivary secretion, decreased concentration of Na+ and K+ in nerve-evoked parotid saliva, as well as effects on parasympathetically-evoked submandibular saliva were described.54

Finally, the literature contrasting SOC ‘General Disorders and Administration Site Conditions’ showed an association between PGs and various chest discomfort events. Such as Stone et al who demonstrated that PGF2α potentiates the effects of cough agents,55 and various sources show that PGE2 causes cough, retrosternal pain, increased sensation of dyspnoea during exercise, as well as the activation of intrapulmonary type C-fibres associated with bronchoconstriction, airway hypersecretion and bronchial vasodilatation.5659 Furthermore, given the involvement of PGs in pain and inflammation mechanisms, their potential to provoke allodynia (touch-evoked pain)60 61 through the sensitisation of smooth muscles and visceral nociceptors,62 could cause chest discomfort. These nociceptors are located in the heart, lung and gastrointestinal tract and are supplied by visceral afferents, which travel through the vagus nerve and cause visceral pain.60 In some cases, the vasoconstriction and PGF2α could be responsible for the cardiac effects.62 Lai et al, demonstrate that PGF2α may play an essential role in the hypertrophy of cardiac ventricular myocytes in vitro and in vivo (cardiac growth),63 probably mediated by the expression of c-fos, atrial natriuretic factor and skeletal actin in cardiac myocyte in animal models. This hypertrophy increases oxygen demand, which could cause angina or ischaemia.64 This, combined with chest discomfort, is also mentioned in the SmPC of latanoprost and travoprost.5 7

No information was found on the possible association of hypoacusis with PGs; on the contrary, many studies show a beneficial effect of PGs in sudden sensorineural hearing loss, alleviating vertigo, disequilibrium and improving hearing in Meniere’s disease.6567

Furthermore, insufficient information has been reported in the scientific literature about skin exfoliation and its possible association with PGs, although it was discovered as an identified risk in the SmPC of bimatoprost.8 We only found information related to inflammation and ageing.68 69

Limitations of the study

Although the FAERS database contains many cases with public access, it has several limitations that could influence the statistical outcomes. For instance, the database’s voluntary reporting system can lead to under-reporting, and the lack of restriction to only health professionals reporting AEs can introduce potential biases. Additionally, the undetermined causality of the AEs reported in the database can make it challenging to establish a clear link between the reported event and a specific product.

Despite the challenges in compensating for the limitations of the FAERS database and replacing it with pharmacovigilance studies, obtain crucial information, especially when dealing with large volumes of data. This is particularly true when the significance of the statistical tests performed is rigorously maintained, ensuring the reliability of the findings.

Conclusion

Of the 12 PTs analysed, 8 of them found information on the possible relationship due to the biological plausibility derived from information from previous research (malignant mediastinal neoplasm, full blood count abnormal, blood immunoglobulin E increased, diabetes mellitus, blepharospasm, cataracts, chest discomfort and dry mouth). Even though it was not possible to affirm that the events’ information was or was not entirely related to PGAs, the evidence obtained is relevant to continue investigating the possible drug-event association, whether to refute the safety signal or identify a new risk with its consequent minimisation.

supplementary material

10.1136/bmjophth-2024-001764 online supplemental table 1

10.1136/bmjophth-2024-001764 online supplemental table 2

Acknowledgements

The authors thank Sarahí Del Carmen Gómez Macías MD for her assistance in writing the medical manuscript.

Data availability statement

Data are available upon reasonable request.

Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Provenance and peer review: Not commissioned; externally peer reviewed.

Patient consent for publication: Not applicable.

Ethics approval: Not applicable.

Data availability free text: The data presented in this article can be accessed from the Food and Drug Administration Adverse Event Reporting System webpage; however, the data is only available on request by the corresponding author.
==== Refs
References

1 Lusthaus JA Goldberg I Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors Expert Opin Emerg Drugs 2016 21 117 28 10.1517/14728214.2016.1151001 26854598
2 Doucette LP Walter MA Prostaglandins in the eye: Function, expression, and roles in glaucoma Ophthalmic Genet 2017 38 108 16 10.3109/13816810.2016.1164193 27070211
3 Kumari A Chapter 16 - prostaglandin synthesis Kumari A Sweet biochemistry Academic Press 2018 85 7
4 Holló G The side effects of the prostaglandin analogues Expert Opin Drug Saf 2007 6 45 52 10.1517/14740338.6.1.45 17181451
5 Pfizer Laboratories/Food and Drug Administration Xalatan- latanoprost Available https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f4e73059-5ba0-4d73-9ea1-09d8d654e844&type=display Accessed 16-Feb-2023
6 Inoue K Managing adverse effects of glaucoma medications Clin Ophthalmol 2014 8 903 13 10.2147/OPTH.S44708 24872675
7 Novartis Pharmaceuticals Corporation / Food and Drug Administration Travatan Z- travoprost Available https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=028455e0-ae77-4213-8819-3b58ef7d6a14&type=display Accessed 27-Jan-2023
8 Allergan Inc./ Latisse- bimatoprost Available https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=34f83d9d-2c64-463e-8a90-9a460fedfead&type=display Accessed 17-Feb-2023
9 Akorn / Food and Drug Administration Zioptan- tafluprost Available https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a3173c26-0e19-47af-a01c-3fc06b2700d1&type=display Accessed 10-Feb-2023
10 Malikova MA Practical applications of regulatory requirements for signal detection and communications in pharmacovigilance Ther Adv Drug Saf 2020 11 2042098620909614 10.1177/2042098620909614 32313617
11 Council for International Organizations of Medical Sciences (CIOMS) Practical aspects of signal detection in pharmacovigilance- report of CIOMS Working Group VIII 2010 Available https://cioms.ch/wp-content/uploads/2018/03/WG8-Signal-Detection.pdf
12 Uppsala Monitoring Centre Signal detection for national pharmacovigilance centres with small data sets 2020 Available http://bit.ly/SmallDataSets
13 European Medicines Agency Guideline on good pharmacovigilance practices (GVP) module IX – signal management 2017 25
14 European Medicines Agency Guideline on good pharmacovigilance practices (GVP) module V– risk management systems (Rev 2) 2017 Available https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf
15 Food and Drug Administration Data mining at FDA -- white paper Available https://www.fda.gov/science-research/data-mining/data-mining-fda-white-paper Accessed 16-Mar-2023
16 Medical Dictionary for Regulatory Activities Welcome to MedDRA Available https://www.meddra.org/ Accessed 23-Jun-2022
17 CIOMS Working Group Practical aspects of signal detection in pharmacovigilance 2010
18 Bate A Bayesian confidence propagation neural network Drug Saf 2007 30 623 5 10.2165/00002018-200730070-00011 17604417
19 Hauben M Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions Clin Ther 2023 45 117 33 10.1016/j.clinthera.2023.01.002 36732152
20 Tada K Maruo K Isogawa N et al Borrowing external information to improve Bayesian confidence propagation neural network Eur J Clin Pharmacol 2020 76 1311 9 10.1007/s00228-020-02909-w 32488331
21 Kim J Kim M Ha J-H et al Signal detection of methylphenidate by comparing a spontaneous reporting database with a claims database Regul Toxicol Pharmacol 2011 61 154 60 10.1016/j.yrtph.2011.03.015 21510997
22 Ventola CL Big Data and Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions P T 2018 43 340 51 29896033
23 Allaj V Guo C Nie D Non-steroid anti-inflammatory drugs, prostaglandins, and cancer Cell Biosci 2013 3 8 10.1186/2045-3701-3-8 23388178
24 Walker OL Dahn ML Power Coombs MR et al The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting Front Oncol 2021 11 791696 10.3389/fonc.2021.791696 35127497
25 Wang D Dubois RN Prostaglandins and cancer Gut 2006 55 115 22 10.1136/gut.2004.047100 16118353
26 Jara-Gutiérrez Á Baladrón V The Role of Prostaglandins in Different Types of Cancer Cells 2021 10 1487 10.3390/cells10061487 34199169
27 Lupulescu A Prostaglandins, their inhibitors and cancer Prostaglandins Leukot Essent Fatty Acids 1996 54 83 94 10.1016/s0952-3278(96)90064-2 8848435
28 Finetti F Travelli C Ercoli J et al Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity Biology (Basel) 2020 9 434 10.3390/biology9120434 33271839
29 Wang Q Morris RJ Bode AM et al Prostaglandin Pathways: Opportunities for Cancer Prevention and Therapy Cancer Res 2022 82 949 65 10.1158/0008-5472.CAN-21-2297 34949672
30 Nie JZ Wang M-T Nie D Regulations of Tumor Microenvironment by Prostaglandins Cancers (Basel) 2023 15 3090 10.3390/cancers15123090 37370700
31 Kim S Lee ES Lee EJ et al Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155 J Exp Clin Cancer Res 2021 40 43 10.1186/s13046-021-01839-4 33494773
32 Carini C Hudspith BN Brostoff J Effect of prostaglandins and cyclic nucleotides on growth and immunoglobulin secretion of two IgE myeloma cell lines Br J Cancer 1981 43 257 60 10.1038/bjc.1981.42 7225278
33 Ulich TR Dakay EB Williams JH et al In vivo induction of neutrophilia, lymphopenia, and diminution of neutrophil adhesion by stable analogs of prostaglandins E1, E2, and F2 alpha Am J Pathol 1986 124 53 8 3728647
34 Weiser-Evans MCM Wang X-Q Amin J et al Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis Cancer Res 2009 69 1733 8 10.1158/0008-5472.CAN-08-3766 19208832
35 Cianferoni A Non-IgE-mediated anaphylaxis J Allergy Clin Immunol 2021 147 1123 31 10.1016/j.jaci.2021.02.012 33832694
36 Gao Y Zhao C Wang W et al Prostaglandins E2 signal mediated by receptor subtype EP2 promotes IgE production in vivo and contributes to asthma development Sci Rep 2016 6 20505 10.1038/srep20505 26852804
37 Finkelberg AB Linares J Goldraij A Glucose metabolism in isolated uteri of immature rats. Influence of prostaglandins and nitric oxide Reprod Nutr Dev 2006 46 1 8 10.1051/rnd:2005057 16438910
38 Truchan NA Fenske RJ Sandhu HK et al Human Islet Expression Levels of Prostaglandin E2 Synthetic Enzymes, But Not Prostaglandin EP3 Receptor, Are Positively Correlated with Markers of β-Cell Function and Mass in Nondiabetic Obesity ACS Pharmacol Transl Sci 2021 4 1338 48 10.1021/acsptsci.1c00045 34423270
39 Carboneau BA Allan JA Townsend SE et al Opposing effects of prostaglandin E2 receptors EP3 and EP4 on mouse and human β-cell survival and proliferation Mol Metab 2017 6 548 59 10.1016/j.molmet.2017.04.002 28580285
40 Robertson RP Prostaglandins, glucose homeostasis, and diabetes mellitus Annu Rev Med 1983 34 1 12 10.1146/annurev.me.34.020183.000245 6344749
41 Kimple ME Keller MP Rabaglia MR et al Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion Diabetes 2013 62 1904 12 10.2337/db12-0769 23349487
42 Meng Z Lv J Luo Y et al Forkhead box O1/pancreatic and duodenal homeobox 1 intracellular translocation is regulated by c-Jun N-terminal kinase and involved in prostaglandin E2-induced pancreatic beta-cell dysfunction Endocrinology 2009 150 5284 93 10.1210/en.2009-0671 19837872
43 Seaquist ER Walseth TF Nelson DM et al Pertussis toxin-sensitive G protein mediation of PGE2 inhibition of cAMP metabolism and phasic glucose-induced insulin secretion in HIT cells Diabetes 1989 38 1439 45 10.2337/diab.38.11.1439 2482818
44 Lee M-L Matsunaga H Sugiura Y et al Prostaglandin in the ventromedial hypothalamus regulates peripheral glucose metabolism Nat Commun 2021 12 2330 10.1038/s41467-021-22431-6 33879780
45 Matsuo K Ban R Ban M Desensitization of the Mechanoreceptors in Müller’s Muscle Reduces the Increased Reflex Contraction of the Orbicularis Oculi Slow-Twitch Fibers in Blepharospasm Eplasty 2014 14 e33 25328566
46 Ruan YC Zhou W Chan HC Regulation of smooth muscle contraction by the epithelium: role of prostaglandins Physiology (Bethesda) 2011 26 156 70 10.1152/physiol.00036.2010 21670162
47 Wang PX Koh VTC Cheng JF Periorbital muscle atrophy associated with topical bimatoprost therapy Clin Ophthalmol 2014 8 311 4 10.2147/OPTH.S55754 24511225
48 Kucukevcilioglu M Bayer A Uysal Y et al Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost Clin Exp Ophthalmol 2014 42 126 31 10.1111/ceo.12163 23844550
49 Andley UP Hebert JS Morrison AR et al Modulation of lens epithelial cell proliferation by enhanced prostaglandin synthesis after UVB exposure Invest Ophthalmol Vis Sci 1994 35 374 81 8112984
50 Goto Y Ibaraki N Miyake K Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol Arch Ophthalmol 2003 121 835 9 10.1001/archopht.121.6.835 12796255
51 Reina S Sterin-Borda L Passafaro D et al Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren’s syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands Arch Oral Biol 2011 56 413 20 10.1016/j.archoralbio.2010.08.017 21371688
52 Gilman KE Camden JM Woods LT et al Indomethacin Treatment Post-irradiation Improves Mouse Parotid Salivary Gland Function via Modulation of Prostaglandin E2 Signaling Front Bioeng Biotechnol 2021 9 697671 10.3389/fbioe.2021.697671 34381764
53 de la Cal C Lomniczi A Mohn CE et al Decrease in salivary secretion by radiation mediated by nitric oxide and prostaglandins Neuroimmunomodulation 2006 13 19 27 10.1159/000093194 16691037
54 Yu J-H Modulating effects of prostaglandins on parasympathetic-mediated secretory activities of rat salivary glands Prostaglandins 1986 31 1087 97 10.1016/0090-6980(86)90212-1 3763940
55 Stone R Barnes PJ Fuller RW Contrasting effects of prostaglandins E2 and F2 alpha on sensitivity of the human cough reflex J Appl Physiol (1985) 1992 73 649 53 10.1152/jappl.1992.73.2.649 1399993
56 Lee LY Widdicombe JG Modulation of airway sensitivity to inhaled irritants: role of inflammatory mediators Environ Health Perspect 2001 109 Suppl 4 585 9 10.1289/ehp.01109s4585 11544168
57 Okazaki A Hara J Ohkura N et al Role of prostaglandin E2 in bronchoconstriction-triggered cough response in guinea pigs Pulm Pharmacol Ther 2018 48 62 70 10.1016/j.pupt.2017.09.003 28951192
58 Lee L-Y Respiratory sensations evoked by activation of bronchopulmonary C-fibers Respir Physiol Neurobiol 2009 167 26 35 10.1016/j.resp.2008.05.006 18586581
59 Tilley SL Hartney JM Erikson CJ et al Receptors and pathways mediating the effects of prostaglandin E2 on airway tone Am J Physiol Lung Cell Mol Physiol 2003 284 L599 606 10.1152/ajplung.00324.2002 12618422
60 Rajan MS Syam P Liu C Systemic side effects of topical latanoprost Eye (Lond) 2003 17 442 4 10.1038/sj.eye.6700351 12724721
61 Minami T Bakoshi S Nakano H et al The effects of capsaicin cream on prostaglandin-induced allodynia Anesth Analg 2001 93 419 23 10.1097/00000539-200108000-00037 11473873
62 Chakrabarty L Systemic side effects of topical prostaglandin analogues: Rare but real Indian J Ophthalmol 2020 68 2637 8 10.4103/ijo.IJO_2039_20 33120724
63 Lai J Jin H Yang R et al Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo Am J Physiol 1996 271 H2197 208 10.1152/ajpheart.1996.271.6.H2197 8997275
64 Mitra M Chang B James T Drug points. Exacerbation of angina associated with latanoprost BMJ 2001 323 783 10.1136/bmj.323.7316.783 11588081
65 Jang CH Cho YB Choi CH et al The effect of topically administered latanoprost on the cochlear blood flow and hearing Int J Pediatr Otorhinolaryngol 2013 77 981 5 10.1016/j.ijporl.2013.03.025 23611671
66 Xi J Liu H Wang X Prostaglandin E1 effects on CD62p and PAC-1 in patients with sudden sensorineural hearing loss Thromb Res 2020 188 31 8 10.1016/j.thromres.2020.01.023 32044505
67 Rask-Andersen H Friberg U Johansson M et al Effects of intratympanic injection of latanoprost in Meniere’s disease: a randomized, placebo-controlled, double-blind, pilot study Otolaryngol Head Neck Surg 2005 133 441 3 10.1016/j.otohns.2005.05.043 16143197
68 Fuller B Role of PGE-2 and Other Inflammatory Mediators in Skin Aging and Their Inhibition by Topical Natural Anti-Inflammatories Cosmetics 2019 6 6 10.3390/cosmetics6010006
69 Satoh T Moroi R Aritake K et al Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor J Immunol 2006 177 2621 9 10.4049/jimmunol.177.4.2621 16888024
